Eliquis
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Eliquis in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Eliquis.
4
Global Revenue Ranking
Recent articles on PMLiVE featuring Eliquis
The company will provide Eliquis, its oral blood thinner, free of charge to Medicaid
New negotiated prices are set to be announced by 1 September 2024 and implemented in 2026
The action comes after the first drugs subject to pricing negotiations were announced
The IRA programme is facing court challenges from leading drugmakers and industry groups
Strong third-quarter revenues of $24.1bn lifted by sales of its BioNTech-partnered COVID-19 vaccine Comirnaty see Pfizer raise its 2021 revenue guidance to $82bn
With revenues for the third quarter up by 10%, BMS hopes growth for Opdivo, Eliquis and new launches will offset inevitable generic competition for Revlimid
In Q2, BMS’ revenue came in at $11.7bn, a 16% increase on the same period last year
COVID-19 vaccine generated $7.8bn in the second quarter of 2021 alone
Full-year guidance for BioNTech-partnered vaccine increased to $26bn
Acquisition will bolster pipeline with targeted cardiovascular therapies
Sales of immunotherapy Opdivo decreased due to COVID-19 impact
BMS share price up by 3% on the back of results
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology